Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group..

J Transl Med. 2011 Jul 11;9:108. doi: 10.1186/1479-5876-9-108.

2.

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group..

Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z.

3.

Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.

Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2015 May;64(5):585-98. doi: 10.1007/s00262-014-1649-1.

4.

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.

Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH.

Cancer Immunol Immunother. 2008 Mar;57(3):289-302.

5.

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.

Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH.

Cancer Immunol Immunother. 2014 Nov;63(11):1199-211. doi: 10.1007/s00262-014-1593-0.

6.

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).

McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S.

Cytometry A. 2013 Aug;83(8):728-38. doi: 10.1002/cyto.a.22319.

7.

Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study.

Yao J, Bechter C, Wiesneth M, Härter G, Götz M, Germeroth L, Guillaume P, Hasan F, von Harsdorf S, Mertens T, Michel D, Döhner H, Bunjes D, Schmitt M, Schmitt A.

Clin Infect Dis. 2008 May 15;46(10):e96-105. doi: 10.1086/587749.

PMID:
18419478
8.

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.

Singh SK, Meyering M, Ramwadhdoebe TH, Stynenbosch LF, Redeker A, Kuppen PJ, Melief CJ, Welters MJ, van der Burg SH.

Cancer Immunol Immunother. 2012 Nov;61(11):1953-63. doi: 10.1007/s00262-012-1251-3.

9.

Harmonization of the intracellular cytokine staining assay.

Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH.

Cancer Immunol Immunother. 2012 Jul;61(7):967-78. doi: 10.1007/s00262-012-1282-9.

10.

Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.

Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P.

J Immunother. 2004 Jul-Aug;27(4):298-308.

PMID:
15235391
11.

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.

Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.

Clin Cancer Res. 2004 Oct 15;10(20):6946-55.

12.

Validation of immunomonitoring methods for application in clinical studies: The HLA-peptide multimer staining assay.

Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, Ottensmeier CH, Gouttefangeas C.

Cytometry B Clin Cytom. 2016 Jul 1. doi: 10.1002/cyto.b.21397. [Epub ahead of print]

PMID:
27363684
13.

Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses.

Lim A, Baron V, Ferradini L, Bonneville M, Kourilsky P, Pannetier C.

J Immunol Methods. 2002 Mar 1;261(1-2):177-94.

PMID:
11861076
14.

Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8(+) T lymphocytes.

Tischer S, Kaireit T, Figueiredo C, Hiller O, Maecker-Kolhoff B, Geyeregger R, Immenschuh S, Blasczyk R, Eiz-Vesper B.

Int Immunol. 2012 Sep;24(9):561-72. doi: 10.1093/intimm/dxs059.

PMID:
22740564
15.

Multimer monitoring of CMV-specific T cells in research and in clinical applications.

Borchers S, Ogonek J, Varanasi PR, Tischer S, Bremm M, Eiz-Vesper B, Koehl U, Weissinger EM.

Diagn Microbiol Infect Dis. 2014 Mar;78(3):201-12. doi: 10.1016/j.diagmicrobio.2013.11.007. Review.

PMID:
24331953
16.
17.

Tracking antigen-specific CD8⁺ T cells using MHC class I multimers.

Alanio C, Bouvier I, Jusforgues-Saklani H, Albert ML.

Methods Mol Biol. 2013;960:309-26. doi: 10.1007/978-1-62703-218-6_23.

PMID:
23329496
18.

CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.

Vikman S, Giandomenico V, Sommaggio R, Oberg K, Essand M, Tötterman TH.

Cancer Immunol Immunother. 2008 Mar;57(3):399-409.

PMID:
17717663
19.

Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.

Supplemental Content

Support Center